TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33187749

Group type: EXPERIMENTAL
Intervention: Postimplementation of pediatric traumatic brain injury guidelines
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Postimplementation of pediatric traumatic brain injury guidelines in severe traumatic brain injury cohort
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Postimplementation of pediatric traumatic brain injury guidelines in severe traumatic brain injury with positive-pressure ventilation
Number of subjects: 2801

Group type: COMPARATOR
Intervention: Preimplementation of pediatric traumatic brain injury guidelines
Number of subjects: 2801
Study: 33188140

Group type: EXPERIMENTAL
Intervention: Paired tumor and plasma ctDNA samples sequenced by target-capture deep sequencing of 1,021 genes.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Paired tissue and ctDNA analysis.
Number of subjects: 300
Study: 33188221

Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation ex situ lung perfusion
Number of subjects: 12
Study: 33188254

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 6005

Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB)
Number of subjects: 6005

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 6005
Study: 33188272

Group type: EXPERIMENTAL
Intervention: Aldosterone-to-renin ratio (ARR) quartiles
Number of subjects: 545
Study: 33188385

Group type: EXPERIMENTAL
Intervention: Azlocillin (100 mg/kg q8h)
Number of subjects: 140
Study: 33188413

Group type: EXPERIMENTAL
Intervention: Maternal diet Cluster I (high intake of plant protein, fiber, and carbohydrates)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maternal diet Cluster II (high intake of animal protein and lipids)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mode of delivery (C-section) with antibiotic exposure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mode of delivery (vaginal birth)
Number of subjects: 120
Study: 33188449

Group type: EXPERIMENTAL
Intervention: Pharmacological modifications of the actin cytoskeleton
Number of subjects: 0
Study: 33188873

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment (43 patients in monocentric cohort, 203 patients in multicentric cohort)
Number of subjects: 435

Group type: COMPARATOR
Intervention: GemPred+ stratification among gemcitabine-treated patients
Number of subjects: 435
Study: 33188997

Group type: EXPERIMENTAL
Intervention: ibrutinib plus R-CHOP
Number of subjects: 21
Study: 33189083

Group type: COMPARATOR
Intervention: Melatonin (up to 10 mg)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Trazodone (50 mg for two weeks)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Ramelteon (8 mg, phase 2 trial)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Orexin antagonists (for four weeks)
Number of subjects: 649
Study: 33189510

Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed activity of the radiopharmaceutical
Number of subjects: 0
Study: 33189632

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 144
Study: 33189854

Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (Enterra therapy)
Number of subjects: 142
Study: 33190086

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) - five single volume plasma exchanges over eight days within a 14-day study period.
Number of subjects: 10
Study: 33190518

Group type: EXPERIMENTAL
Intervention: Post-traumatic growth (PTG) recognized through the disclosure process
Number of subjects: 22
Study: 33190629

Group type: EXPERIMENTAL
Intervention: ≥50 mL/(kg · day) human milk
Number of subjects: 964
Study: 33191112

Group type: EXPERIMENTAL
Intervention: Relebactam/imipenem/cilastatin (250 mg/500 mg/500 mg) dosed every 6 h for 5-14 days
Number of subjects: 81
Study: 33191168

Group type: EXPERIMENTAL
Intervention: Hyper-CVAD Regimen
Number of subjects: 0
Study: 33191169

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posttransplantation care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal residual disease measurement and preemptive therapies
Number of subjects: 0
Study: 33191282

Group type: EXPERIMENTAL
Intervention: Pain (visual analog scale)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Fatigue (visual analog scale)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Standard components of disease activity (SJC/TJC, CRP, ESR, PhGH, PaGH)
Number of subjects: 379
Study: 33191407

Group type: EXPERIMENTAL
Intervention: HPV integration signatures
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Episomal HPV in PIK3CA mutated tumours
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: High HPV copy number
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: HPV genotype
Number of subjects: 272
Study: 33191524

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 86
Study: 33191769

Group type: EXPERIMENTAL
Intervention: Coronary Optical Coherence Tomography (OCT) and Cardiac Magnetic Resonance (CMR) imaging
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR) imaging
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Multimodality imaging with coronary OCT and CMR
Number of subjects: 301
Study: 33191774

Group type: EXPERIMENTAL
Intervention: F/TDF at 33% of daily dosing
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: F/TDF at 67% of daily dosing
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: F/TDF at 100% of daily dosing
Number of subjects: 48
Study: 33192054

Group type: EXPERIMENTAL
Intervention: Patient-reported experience measures (PREMs)
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Statistical methods from item response theory (IRT)
Number of subjects: 1932
Study: 33192400

Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+ S device stimulation in the supplementary motor area (SMA) and ventral capsule/ventral striatum (VC/VS)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Cortical stimulation (blinded)
Number of subjects: 1
Study: 33192485

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined Training (COMB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list Control Group
Number of subjects: 96
Study: 33192504

Group type: EXPERIMENTAL
Intervention: Spironolactone, dosage and duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dry Extract, dosage and duration not specified
Number of subjects: 0
Study: 33192706

Group type: EXPERIMENTAL
Intervention: RG7203 (two doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 33192959

Group type: EXPERIMENTAL
Intervention: Immunomodulatory Probiotic Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33193001

Group type: EXPERIMENTAL
Intervention: sEMG Assessment during Overground Robot-Assisted Gait Training
Number of subjects: 0
Study: 33193013

Group type: EXPERIMENTAL
Intervention: Single-stage combined embolization and resection
Number of subjects: 0
Study: 33193052

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal instrumented assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33193314

Group type: EXPERIMENTAL
Intervention: Coagulation/complement factors (C3, C4, C4a, C9, PT, aPTT, fibrinogen, factor II, VIII, and X, D-dimer, antithrombin, protein C, protein S, von-Willebrand factor)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast-enhanced MRI
Number of subjects: 90

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 90
Study: 33193670

Group type: EXPERIMENTAL
Intervention: Carriers of the A allele (27.6%)
Number of subjects: 116
Study: 33194177

Group type: EXPERIMENTAL
Intervention: DNA methylation profiling using Reduced Representation Bisulfite Sequencing (RRBS) in CD04
Number of subjects: 0
Study: 33194595

Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccination
Number of subjects: 21
Study: 33194670

Group type: EXPERIMENTAL
Intervention: OxyChip Implantation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electron Paramagnetic Resonance Oximetry
Number of subjects: 24
Study: 33194700

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 453

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 453
Study: 33194741

Group type: EXPERIMENTAL
Intervention: IRX195183, a RARα-Selective CYP26 Resistant Retinoid
Number of subjects: 0
Study: 33194913

Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion (FETO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management (non-FETO)
Number of subjects: 0
Study: 33195311

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 33195457

Group type: EXPERIMENTAL
Intervention: Pacemaker intervention, specific details not available
Number of subjects: 0
Study: 33195707

Group type: EXPERIMENTAL
Intervention: Partial meniscectomy (n = 139)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Physical therapy (n = 147)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 321
Study: 33195874

Group type: EXPERIMENTAL
Intervention: Higher frequency point-of-care (POC) viral load (VL) and targeted drug resistance mutation (DRM) testing
Number of subjects: 704

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 704
Study: 33196448

Group type: EXPERIMENTAL
Intervention: mHealth app promoting healthy eating habits
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard primary care
Number of subjects: 200
Study: 33196449

Group type: EXPERIMENTAL
Intervention: Self-administered intervention with assistance via chat
Number of subjects: 166

Group type: COMPARATOR
Intervention: Self-administered intervention without assistance via chat
Number of subjects: 166
Study: 33196581

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer DES (Synergy)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Durable polymer DES (Resolute Integrity, Xience, Ion, or Promus)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DAPT discontinuation <6 months after PCI
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resuming or starting cancer treatment (chemotherapy, radiation therapy, or surgery) after PCI
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DAPT interruption
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Advanced cancer
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Discontinuation of aspirin and early P2Y12 inhibitor discontinuation
Number of subjects: 75
Study: 33196758

Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1% (once daily for 3 or 5 days over 25 cm2)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1% (once daily for 3 or 5 days over 25 or 100 cm2)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1%
Number of subjects: 198
Study: 33196852

Group type: EXPERIMENTAL
Intervention: Unilateral hopping exercises (6 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control leg (CL)
Number of subjects: 10
Study: 33196868

Group type: EXPERIMENTAL
Intervention: D
Number of subjects: 15
Study: 33197289

Group type: EXPERIMENTAL
Intervention: Amoxicillin + metronidazole + SRP
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Metronidazole + SRP
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Azithromycin + SRP
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanate + SRP
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Doxycycline + SRP
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Tetracycline + SRP
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: Clindamycin + SRP
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Doxycycline + SRP versus metronidazole + SRP
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Clindamycin + SRP versus metronidazole + SRP
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Clindamycin + SRP versus doxycycline + SRP
Number of subjects: 2664
Study: 33197293

Group type: EXPERIMENTAL
Intervention: Metabolic surgery
Number of subjects: 535

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 535
Study: 33197825

Group type: EXPERIMENTAL
Intervention: Educational and exercise program (physiotherapy guided education and group-based or home exercise sessions, biweekly for approximately eight weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Educational and exercise program
Number of subjects: 32
Study: 33197925

Group type: EXPERIMENTAL
Intervention: CC-90009
Number of subjects: 35
Study: 33197929

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: (val)ganciclovir, foscarnet, cidofovir
Number of subjects: 0
Study: 33198536

Group type: EXPERIMENTAL
Intervention: Hospital Asthma Severity Score (HASS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pediatric Respiratory Assessment Measure (PRAM)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 58
Study: 33198571

Group type: EXPERIMENTAL
Intervention: Total liquid ventilation (TLV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normothermic follow-up)
Number of subjects: 0
Study: 33198661

Group type: EXPERIMENTAL
Intervention: Resected malignant carcinoma
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Benign pancreatic disease
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Advanced disease (inoperable)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CK-positive cells in resected malignant cases
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CK-positive cells in advanced disease
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CK-positive cells in benign disease
Number of subjects: 242

Group type: COMPARATOR
Intervention: Presence of CK-positive cells
Number of subjects: 242
Study: 33198671

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg orally once daily in 28-day cycles
Number of subjects: 26
Study: 33198674

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic chemotherapy, HIPEC and CRS (conversion therapy group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy and HIPEC (palliative chemotherapy group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic chemotherapy and HIPEC
Number of subjects: 40
Study: 33198695

Group type: EXPERIMENTAL
Intervention: Multidisciplinary audit
Number of subjects: 0
Study: 33198781

Group type: EXPERIMENTAL
Intervention: Lung cancer screening with baseline health questionnaire, spirometry, and low-dose CT scan.
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Multivariate model based on age, current smoking status, number of pack-years, presence of dyspnea, wheeze, high-risk occupation, and emphysema extent on LDCT.
Number of subjects: 2514
Study: 33198942

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy (IMPT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Passive Scattering Proton Therapy (PSPT)
Number of subjects: 139
Study: 33199155

Group type: EXPERIMENTAL
Intervention: CPL304110 (pyrazole-benzimidazole derivative)
Number of subjects: 0
Study: 33199195

Group type: EXPERIMENTAL
Intervention: Short training sessions for nurses on identifying STEMI patients
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Typical STEMI ECG signs
Number of subjects: 327

Group type: COMPARATOR
Intervention: Delayed group (D2B>70min)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Non-delayed group (D2B≤70min)
Number of subjects: 327
Study: 33199247

Group type: EXPERIMENTAL
Intervention: Evolut PRO valve
Number of subjects: 60
Study: 33199389

Group type: EXPERIMENTAL
Intervention: Cipargamin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33199417

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1199
Study: 33199511

Group type: EXPERIMENTAL
Intervention: Nab-Pac followed by epirubicin and cyclophosphamide (EC)
Number of subjects: 56
Study: 33199608

Group type: EXPERIMENTAL
Intervention: Visible orientation-defined figures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invisible orientation-defined figures
Number of subjects: 0
Study: 33199917

Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Number of subjects: 10754

Group type: EXPERIMENTAL
Intervention: Genetic correlation analysis
Number of subjects: 10754

Group type: EXPERIMENTAL
Intervention: Gene mapping and heritability enrichment
Number of subjects: 10754

Group type: EXPERIMENTAL
Intervention: Drug-target enrichment analysis
Number of subjects: 10754

Group type: EXPERIMENTAL
Intervention: Analysis of genetic risks
Number of subjects: 10754
Study: 33200126

Group type: EXPERIMENTAL
Intervention: Risk assessment framework for trial activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance on protective measures
Number of subjects: 0
Study: 33200217

Group type: EXPERIMENTAL
Intervention: Sirolimus (oral administration, dose-adjusted to maintain a therapeutic range of 6-15 ng/ml for 6 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sirolimus (oral administration)
Number of subjects: 20
Study: 33200394

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) without concomitant MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (ADA) with concomitant MTX
Number of subjects: 0
Study: 33200890

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 33200900

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study: 33200999

Group type: EXPERIMENTAL
Intervention: FAITH! App
Number of subjects: 9
Study: 33201228

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33201358

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan 50 or 70 mg/m²
Number of subjects: 29
Study: 33201438

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 10355
Study: 33201789

Group type: EXPERIMENTAL
Intervention: Subharmonic-aided pressure estimation (SHAPE) using a US contrast agent and saline infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatic venous pressure gradient (HVPG) measurements
Number of subjects: 0
Study: 33201788

Group type: EXPERIMENTAL
Intervention: Mean Apparent Diffusion Coefficient (ADC) values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate calculations of ADC
Number of subjects: 0
Study: 33201924

Group type: EXPERIMENTAL
Intervention: Bio-sonographic index (BSI) evaluated at baseline, 6 hours, and 24 hours after the procedure.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bio-sonographic index (BSI)
Number of subjects: 80
Study: 33202069

Group type: EXPERIMENTAL
Intervention: AQUAped questionnaire
Number of subjects: 133
Study: 33203317

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention to support memory and brain health, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not specified
Number of subjects: 0
Study: 33203623

Group type: EXPERIMENTAL
Intervention: 13C-sucrose breath test
Number of subjects: 0
Study: 33203626

Group type: EXPERIMENTAL
Intervention: ABCC tool used during regular consultations
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 33203644

Group type: EXPERIMENTAL
Intervention: Entinostat plus Pembrolizumab
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 33203645

Group type: EXPERIMENTAL
Intervention: Neratinib at 240 mg/day with cetuximab (standard dosage)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neratinib at lower doses (120 mg, 160 mg, 200 mg) with cetuximab (standard dosage)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 33203665

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily from day 1 plus nivolumab 3 mg/kg intravenously on day 15, then every 2 weeks (phase Ib)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg for the first 14 days (induction) then 25 mg per day plus nivolumab on the same schedule (phase II)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sunitinib plus nivolumab
Number of subjects: 68
Study: 33203723

Group type: EXPERIMENTAL
Intervention: Airway hyper-responsiveness
Number of subjects: 0
Study: 33204013

Group type: EXPERIMENTAL
Intervention: Pre-emptive TKIs strategy based on BCR/ABL molecular monitoring
Number of subjects: 167

Group type: COMPARATOR
Intervention: Prophylactic TKIs from historical data
Number of subjects: 167
Study: 33204020

Group type: EXPERIMENTAL
Intervention: Achondroplasia participants
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (UK Biobank participants)
Number of subjects: 49
Study: 33204145

Group type: EXPERIMENTAL
Intervention: 10 kHz SCS
Number of subjects: 43
Study: 33204764

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (once-daily)
Number of subjects: 2795

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (twice-weekly)
Number of subjects: 2795

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (once-weekly)
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2795
Study: 33205032

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with bevacizumab (Group A) for cycles 3-6
Number of subjects: 142

Group type: COMPARATOR
Intervention: Neoadjuvant therapy without bevacizumab (Group B) for cycles 3-6
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Overall intervention based on early PET assessment
Number of subjects: 142
Study: 33205058

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0